Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-TTRSC04 in healthy subjects
NCT05661916Phase 1Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jan 2023
- Primary completion
- Sep 2025
- Modality
- Lipid-based Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Transthyretin amyloidosis (ATTR) comparing ALN-TTRSC04 with Placebo (2 arms). Primary endpoint: Frequency of Adverse Events at 20 months. Started Jan 2023; status: completed.
02
Drugs
nucresiran
03
Conditions
Transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT05661916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05661916.